134 related articles for article (PubMed ID: 37869087)
1. Abscopal effect in metastatic breast cancer treated with stereotactic body radiotherapy in the absence of immunotherapy.
Kim JS; Chang AR
Front Oncol; 2023; 13():1243053. PubMed ID: 37869087
[TBL] [Abstract][Full Text] [Related]
2. Post-radiation neutrophil-to-lymphocyte ratio is a prognostic marker in patients with localized pancreatic adenocarcinoma treated with anti-PD-1 antibody and stereotactic body radiation therapy.
Reddy AV; Hill CS; Sehgal S; Zheng L; He J; Laheru DA; Jesus-Acosta A; Herman JM; Meyer J; Narang AK
Radiat Oncol J; 2022 Jun; 40(2):111-119. PubMed ID: 35796114
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic Body Radiotherapy (SBRT) for Spinal Metastases: Who Will Benefit the Most from SBRT?
Park HJ; Kim HJ; Won JH; Lee SC; Chang AR
Technol Cancer Res Treat; 2015 Apr; 14(2):159-67. PubMed ID: 24502552
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic body radiotherapy (SBRT) for pulmonary metastases from renal cell carcinoma-a multicenter analysis of the German working group "Stereotactic Radiotherapy".
Hoerner-Rieber J; Duma M; Blanck O; Hildebrandt G; Wittig A; Lohaus F; Flentje M; Mantel F; Krempien R; Eble MJ; Kahl KH; Boda-Heggemann J; Rieken S; Guckenberger M
J Thorac Dis; 2017 Nov; 9(11):4512-4522. PubMed ID: 29268521
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic body radiation therapy in combination with systemic therapy for metastatic renal cell carcinoma: a prospective multicentre study.
Dengina N; Mitin T; Gamayunov S; Safina S; Kreinina Y; Tsimafeyeu I
ESMO Open; 2019; 4(5):e000535. PubMed ID: 31673426
[TBL] [Abstract][Full Text] [Related]
6. Clinical Outcomes and Prognostic Factors of Salvage Stereotactic Body Radiotherapy for Post-Surgical Thoracic Oligo-Recurrence/Metastasis of Non-Small-Cell Lung Cancer.
Li WC; Wang Z; Gao J; Zhou H; Li J; Zhu XX
Cancer Manag Res; 2021; 13():1887-1896. PubMed ID: 33654433
[TBL] [Abstract][Full Text] [Related]
7. Vertebral compression fractures after stereotactic body radiation therapy: a large, multi-institutional, multinational evaluation.
Jawad MS; Fahim DK; Gerszten PC; Flickinger JC; Sahgal A; Grills IS; Sheehan J; Kersh R; Shin J; Oh K; Mantel F; Guckenberger M;
J Neurosurg Spine; 2016 Jun; 24(6):928-36. PubMed ID: 26895526
[TBL] [Abstract][Full Text] [Related]
8. Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio in Hepatocellular Carcinoma Treated with Stereotactic Body Radiotherapy.
Park Y; Chang AR
Korean J Gastroenterol; 2022 Jun; 79(6):252-259. PubMed ID: 35746839
[TBL] [Abstract][Full Text] [Related]
9. Survival Is Worse in Patients Completing Immunotherapy Prior to SBRT/SRS Compared to Those Receiving It Concurrently or After.
Woody S; Hegde A; Arastu H; Peach MS; Sharma N; Walker P; Ju AW
Front Oncol; 2022; 12():785350. PubMed ID: 35692764
[TBL] [Abstract][Full Text] [Related]
10. High neutrophil-to-lymphocyte ratio following stereotactic body radiation therapy is associated with poor clinical outcomes in patients with borderline resectable and locally advanced pancreatic cancer.
Reddy AV; Hill CS; Sehgal S; He J; Zheng L; Herman JM; Meyer J; Narang AK
J Gastrointest Oncol; 2022 Feb; 13(1):368-379. PubMed ID: 35284125
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study.
Masini C; Iotti C; De Giorgi U; Bellia RS; Buti S; Salaroli F; Zampiva I; Mazzarotto R; Mucciarini C; Vitale MG; Bruni A; Lohr F; Procopio G; Caffo O; Nole F; Morelli F; Baier S; Buttigliero C; Ciammella P; Timon G; Fantinel E; Carlinfante G; Berselli A; Pinto C
Eur Urol; 2022 Mar; 81(3):274-282. PubMed ID: 34602312
[TBL] [Abstract][Full Text] [Related]
12. Abscopal Effect after Stereotactic Body Radiotherapy with Nivolumab for Lung Metastasis of Head and Neck Cancer: A Case Report.
Endo M; Fukuda Y; Okada K; Ogawa K; Nakamura M; Takahashi S; Kawahara M; Akahane K; Nagai Y; Yamaguchi H; Nishino H; Mori H; Shirai K
Case Rep Oncol; 2023; 16(1):1345-1352. PubMed ID: 37946746
[TBL] [Abstract][Full Text] [Related]
13. Ten-Year Outcomes of Stereotactic Body Radiotherapy for Oligometastatic Breast Cancer: Does Synchronous Oligometastatic Breast Cancer Benefit?
Nagpal SK; Khabra K; Ross G; Kirby AM
Clin Oncol (R Coll Radiol); 2023 Nov; 35(11):736-743. PubMed ID: 37684189
[TBL] [Abstract][Full Text] [Related]
14. Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how?
Marvaso G; Corrao G; Oneta O; Pepa M; Zaffaroni M; Corso F; Gandini S; Cecconi A; Zerini D; Mazzola GC; Augugliaro M; Cossu Rocca M; Verri E; Cattani F; La Fauci F; Bergamaschi L; Luzzago S; Mistretta AF; Musi G; Nolè F; De Cobelli O; Orecchia R; Jereczek-Fossa BA
Clin Transl Oncol; 2021 Aug; 23(8):1717-1726. PubMed ID: 33687659
[TBL] [Abstract][Full Text] [Related]
15. Novel stereotactic body radiation therapy (SBRT)-based partial tumor irradiation targeting hypoxic segment of bulky tumors (SBRT-PATHY): improvement of the radiotherapy outcome by exploiting the bystander and abscopal effects.
Tubin S; Popper HH; Brcic L
Radiat Oncol; 2019 Jan; 14(1):21. PubMed ID: 30696472
[TBL] [Abstract][Full Text] [Related]
16. A Large, Multicenter, Retrospective Study on Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups.
Macchia G; Lazzari R; Colombo N; Laliscia C; Capelli G; D'Agostino GR; Deodato F; Maranzano E; Ippolito E; Ronchi S; Paiar F; Scorsetti M; Cilla S; Ingargiola R; Huscher A; Cerrotta AM; Fodor A; Vicenzi L; Russo D; Borghesi S; Perrucci E; Pignata S; Aristei C; Morganti AG; Scambia G; Valentini V; Jereczek-Fossa BA; Ferrandina G
Oncologist; 2020 Feb; 25(2):e311-e320. PubMed ID: 32043791
[TBL] [Abstract][Full Text] [Related]
17. Impact of stereotactic body radiotherapy (SBRT) in oligoprogressive metastatic disease.
Ramadan S; Quan K; Schnarr K; Juergens RA; Hotte SJ; Mukherjee SD; Kapoor A; Meyers BM; Swaminath A
Acta Oncol; 2022 Jun; 61(6):705-713. PubMed ID: 35435129
[TBL] [Abstract][Full Text] [Related]
18. Extracranial Stereotactic Body Radiotherapy in Oligometastatic or Oligoprogressive Breast Cancer.
Weykamp F; König L; Seidensaal K; Forster T; Hoegen P; Akbaba S; Mende S; Welte SE; Deutsch TM; Schneeweiss A; Debus J; Hörner-Rieber J
Front Oncol; 2020; 10():987. PubMed ID: 32676455
[No Abstract] [Full Text] [Related]
19. Stereotactic body radiotherapy extends the clinical benefit of PD-1 inhibitors in refractory recurrent/metastatic nasopharyngeal carcinoma.
Lin J; Guo Q; Guo Z; Lu T; Chen G; Lin S; Chen M; Chen C; Lu J; Zong J; Tang L; Chen Y; Pan J
Radiat Oncol; 2022 Jul; 17(1):117. PubMed ID: 35790987
[TBL] [Abstract][Full Text] [Related]
20. Postoperative re-irradiation using stereotactic body radiotherapy for metastatic epidural spinal cord compression.
Ito K; Nihei K; Shimizuguchi T; Ogawa H; Furuya T; Sugita S; Hozumi T; ; Karasawa K
J Neurosurg Spine; 2018 Sep; 29(3):332-338. PubMed ID: 29905524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
